Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00058487 · ClinicalTrials.gov registry record · Phase 2
Epirubicin and Thalidomide in Treating Patients With Liver Cancer
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00058487 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 12 participants.
The verdict
NCT00058487, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy such as epirubicin use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of hepatocellular (liver) cancer by stopping blood flow to the tumor. Combining epirubicin with thalidomide may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining epirubicin with thalidomide in treating patients who have unresectable or metastatic liver cancer.
Interventions
- DRUG epirubicin hydrochloride
- DRUG thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2001-12 |
| Est. Completion | 2007-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00058487
The ClinicalTrials.gov registry entry for NCT00058487 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which epirubicin hydrochloride is the first listed.
NCT00058487 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00058487 about?
NCT00058487 is a clinical study titled "Epirubicin and Thalidomide in Treating Patients With Liver Cancer". RATIONALE: Drugs used in chemotherapy such as epirubicin use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of hepatocellular (liver) cancer by stopping blood flow to the tumor. Combining epirubicin with thalidomide may kill more tumor c...
What is the current status of trial NCT00058487?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2001-12. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00058487?
The interventions under investigation include: epirubicin hydrochloride (DRUG), thalidomide (DRUG).
Who is sponsoring clinical trial NCT00058487?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.